A Double Blind, Randomized, Placebo Controlled Study to Determine the Physiological Effectiveness of Januvia for Reducing Inflammation and Increasing EPC Number in HIV Infected Men and Women With Insulin Resistance and Central Adiposity.
The clinical trial investigates the efficacy of Januvia (sitagliptin) in reducing inflammation and improving endothelial function in HIV-infected individuals with insulin resistance and cardiovascular disease risk factors. Given the high prevalence of diabetes and cardiovascular complications in this population, successful outcomes could position sitagliptin as a novel therapeutic option, expanding its market beyond diabetes management to include HIV-related cardiometabolic complications. This could enhance Merck's portfolio and provide a competitive edge in the growing market for treatments addressing comorbidities in HIV patients. Diligence should focus on the regulatory landscape and potential reimbursement pathways for this indication.
Indication: Inflammation
Modality: small molecule
Target: Dipeptidyl peptidase-IV (DPP4)
Sponsor: Washington University School of Medicine
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jun 25, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Dipeptidyl peptidase-IV (DPP4)
View original source fields
Condition raw: Inflammation, Macrophage Infiltration, Cardiovascular Disease
Condition normalized: Inflammation, Macrophage Infiltration, Cardiovascular Disease
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Dipeptidyl peptidase-IV (DPP4)
Target normalized: Dipeptidyl peptidase-IV (DPP4)